AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24361227 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC29A1 GA haplotype
Number of subjects: 324
Study 24361227 — intervention group
Group type: EXPERIMENTAL
Intervention: RRM1 SNP (rs9937) and haplotypes ATAA and ATGA
Number of subjects: 324
Study 22120252 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nimodipine
Number of subjects: 171
Study 22120252 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nimodipine
Number of subjects: 171
Study 19130963 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 37
Study 19130963 — intervention group
Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 37
Study 17230307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve decompression without transposition
Number of subjects: 66
Study 17230307 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous anterior transposition of the nerve
Number of subjects: 66
Study 15241758 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy for the paretic upper limb (sensorimotor active‐assistive exercise or progressive‐resistive training)
Number of subjects: 42
Study 11782827 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20g/d)
Number of subjects: 16
Study 11782827 — intervention group
Group type: COMPARATOR
Intervention: Placebo maltodextrin powder
Number of subjects: 16
Study 9696215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 64
Study 9696215 — intervention group
Group type: COMPARATOR
Intervention: No bromocriptine treatment (Control)
Number of subjects: 64
Study 7808246 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (6 g.d-1)
Number of subjects: 0
Study 7808246 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration (2000 units 15 min prior to exercise)
Number of subjects: 0
Study 7808246 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study 2532868 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 17
Study 2532868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 938185 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy alone
Number of subjects: 0
Study 938185 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 938185 — intervention group
Group type: COMPARATOR
Intervention: Drug alone
Number of subjects: 0
Study 938185 — intervention group
Group type: COMPARATOR
Intervention: Drug plus psychotherapy
Number of subjects: 0
Study 938185 — intervention group
Group type: EXPERIMENTAL
Intervention: Milieu therapy
Number of subjects: 0
Study 29782228 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention
Number of subjects: 0
Study 28582809 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) 1.0 g twice a day for 12 weeks
Number of subjects: 100
Study 28582809 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 100
Study 24599830 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 113
Study 24599830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 113
Study 24599830 — intervention group
Group type: COMPARATOR
Intervention: Phosphorus-restricted diet
Number of subjects: 113
Study 23388530 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal (10 mg a day for 10‐20 minutes before meals) and Rozaliak cream (2 times a day)
Number of subjects: 25
Study 23388530 — intervention group
Group type: COMPARATOR
Intervention: Control group received a full comprehensive treatment complex including short courses of antibiotics, systemic metronidazole, antihistamines, desensitizing agents, traditional external therapy (Rosamet, 0.75% metronidazole cream)
Number of subjects: 25
Study 23388530 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal and Rozaliak cream
Number of subjects: 25
Study 23388530 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment
Number of subjects: 25
Study 21612650 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning (RPS)
Number of subjects: 40
Study 21612650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting forward lean (SFL)
Number of subjects: 40
Study 21612650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting knee extension (SKE)
Number of subjects: 40
Study 21612650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bent knee fall out (BKFO)
Number of subjects: 40
Study 21612650 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg lowering (LL)
Number of subjects: 40
Study 19388883 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-crank exercise training (twice weekly for 12 weeks)
Number of subjects: 57
Study 19388883 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 57
Study 16978278 — intervention group
Group type: EXPERIMENTAL
Intervention: Introital ultrasonography (IUS) with a convex probe
Number of subjects: 383
Study 15549277 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 94
Study 15549277 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisoprodol (700 mg)
Number of subjects: 94
Study 15549277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 94
Study 11544435 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3.4 g/day)
Number of subjects: 45
Study 11544435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9333880 — intervention group
Group type: EXPERIMENTAL
Intervention: Former workers exposed to fluoride
Number of subjects: 169
Study 9333880 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 men not exposed to fluoride)
Number of subjects: 169
Study 8316658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose radiotherapy (LD‐RT) of 5 x 2 Gy (arm A: 32 patients)
Number of subjects: 60
Study 8316658 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose radiotherapy (HD‐RT) of either 10 x 2 Gy (arm B1; 8 patients) or 5 x 3.5 Gy (arm B2; 20 patients)
Number of subjects: 60
Study 8316658 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional diphosphonates
Number of subjects: 60
Study 8316658 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication
Number of subjects: 60
Study 8316658 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60
Study 3593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 0
Study 3593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 15 mg
Number of subjects: 0
Study 3593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 40 mg
Number of subjects: 0
Study 3593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 1 mg (IV)
Number of subjects: 0
Study 3593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 3 mg (IV)
Number of subjects: 0
Study 30647815 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI > 30 kg/m2)
Number of subjects: 61
Study 30647815 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (25 kg/m2 < BMI < 30 kg/m2)
Number of subjects: 61
Study 30647815 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMI < 25 kg/m2)
Number of subjects: 61
Study 27371769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILS)
Number of subjects: 886
Study 27371769 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 886
Study 27371769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study 24828850 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB group (20 mL of 0.5% bupivacaine in the T9‐10 paravertebral space)
Number of subjects: 50
Study 24828850 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB group
Number of subjects: 50
Study 24828850 — intervention group
Group type: COMPARATOR
Intervention: Control group (only general anesthesia)
Number of subjects: 50
Study 24828850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 22397953 — intervention group
Group type: EXPERIMENTAL
Intervention: tocilizumab (4 or 8 mg/kg)
Number of subjects: 299
Study 21062179 — intervention group
Group type: EXPERIMENTAL
Intervention: Revolution IQ with Quick Release (QR)
Number of subjects: 25
Study 21062179 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional (Trad)
Number of subjects: 25
Study 21062179 — intervention group
Group type: EXPERIMENTAL
Intervention: ION 4D (ION)
Number of subjects: 25
Study 21062179 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional with hardware altered (TradAlt)
Number of subjects: 25
Study 21062179 — intervention group
Group type: EXPERIMENTAL
Intervention: Revolution IQ with Quick Release hardware altered (QRAlt)
Number of subjects: 25
Study 19067812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping and ablation of AFL using the CARTO 3D mapping system (Biosense Webster, Diamond Bar, CA, USA)
Number of subjects: 220
Study 19067812 — intervention group
Group type: COMPARATOR
Intervention: No further ablation
Number of subjects: 220
Study 16685051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 10 mg tablets twice a day during hospitalization
Number of subjects: 299
Study 16685051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 16685051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 299
Study 15324519 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% (Opatanol; Patanol)
Number of subjects: 100
Study 15324519 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen 0.025% (Zaditen; Zaditor)
Number of subjects: 100
Study 11502700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestick resuscitation
Number of subjects: 50
Study 11502700 — intervention group
Group type: COMPARATOR
Intervention: Conventional resuscitation
Number of subjects: 50
Study 9301400 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 60 mg kg‐1
Number of subjects: 30
Study 9301400 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 8419695 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 60
Study 8419695 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin combined with thymopentin
Number of subjects: 60
Study 8419695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunomodulatory therapy)
Number of subjects: 60
Study 2943311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg daily)
Number of subjects: 21
Study 2943311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30497077 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Turkish music therapy
Number of subjects: 75
Study 30497077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 75
Study 30316305 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with the decision aid
Number of subjects: 0
Study 30316305 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing alone (control)
Number of subjects: 0
Study 26694904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity shock wave treatment (12 sessions of 1,500 pulses of 0.09 mJ/mm(2) at 120 shock waves per minute)
Number of subjects: 58
Study 26694904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity shock wave treatment
Number of subjects: 58
Study 26694904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity shock wave treatment after sham treatment
Number of subjects: 58
Study 26694904 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 58
Study 25223173 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa 3.6 mg by subcutaneous injection starting from the 1st day to the 5th day of menstruation, once per 28 days (Observation 1 group)
Number of subjects: 134
Study 25223173 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa 3.6 mg by subcutaneous injection in combination with Wenshen Xiaozheng Decoction (WXD) starting from the 1st day to the 5th day of menstruation, once per 28 days, plus WXD for 7 doses, one cycle per every 28 days (Observation 2 group)
Number of subjects: 134
Study 25223173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 134
Study 25223173 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 134
Study 22710267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 1773
Study 22710267 — intervention group
Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 1773
Study 20578384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 196
Study 20578384 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Tiapride tablets)
Number of subjects: 196
Study 17672075 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 60
Study 17672075 — intervention group
Group type: COMPARATOR
Intervention: Warfarin and low-dose ASA
Number of subjects: 60
Study 17672075 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*3 variant
Number of subjects: 60
Study 17672075 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype determination
Number of subjects: 60
Study 14692964 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced blood products
Number of subjects: 645
Study 14692964 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-leukoreduced blood products)
Number of subjects: 645
Study 14692964 — intervention group
Group type: EXPERIMENTAL
Intervention: Study patients who did not receive transfusion
Number of subjects: 645
Study 14692964 — intervention group
Group type: COMPARATOR
Intervention: Control patients who did not receive transfusion
Number of subjects: 645
Study 11782647 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (male)
Number of subjects: 33
Study 11782647 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (female)
Number of subjects: 33
Study 11782647 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (both genders)
Number of subjects: 33
Study 11782647 — intervention group
Group type: COMPARATOR
Intervention: Controls (male)
Number of subjects: 33
Study 11782647 — intervention group
Group type: COMPARATOR
Intervention: Controls (female)
Number of subjects: 33
Study 9825249 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate maintenance therapy
Number of subjects: 62
Study 7544932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser ablation of the prostate (ELAP)
Number of subjects: 151
Study 7544932 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 151
Study 2553326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (0.18 g of N + 125 kJ day‐1 kg‐1) for 3 or 7 days before laparotomy
Number of subjects: 30
Study 2553326 — intervention group
Group type: COMPARATOR
Intervention: Hospital diet only
Number of subjects: 30
Study 2553326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition
Number of subjects: 30
Study 1054609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibromomannitol (DBM)
Number of subjects: 40
Study 1054609 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 40
Study 31538703 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI)
Number of subjects: 66126
Study 31538703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (HF)
Number of subjects: 66126
Study 31538703 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional whole breast RT (CWBI)
Number of subjects: 66126
Study 31538703 — intervention group
Group type: EXPERIMENTAL
Intervention: No RT
Number of subjects: 66126
Study 31538703 — intervention group
Group type: COMPARATOR
Intervention: Omission of RT
Number of subjects: 66126
Study 31538703 — intervention group
Group type: EXPERIMENTAL
Intervention: HF
Number of subjects: 66126
Study 31538703 — intervention group
Group type: COMPARATOR
Intervention: T1N0 subgroup analysis
Number of subjects: 66126
Study 30415141 — intervention group
Group type: EXPERIMENTAL
Intervention: Information package (brochure, video, personalized phone call reminder) delivered through home visits by specially trained agents
Number of subjects: 2000
Study 30415141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information package)
Number of subjects: 2000
Study 28934714 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 75mg/day
Number of subjects: 60
Study 28934714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25962885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (multifaceted, interdisciplinary KT intervention)
Number of subjects: 5478
Study 25962885 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 5478
Study 23598900 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual walking training program using a real-world video recording for 30 mins a day, three times a week, for 6 weeks
Number of subjects: 14
Study 23598900 — intervention group
Group type: COMPARATOR
Intervention: Treadmill gait training for 30 mins a day, three times a week, for 6 weeks
Number of subjects: 14
Study 23598900 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual walking training program using a real-world video recording
Number of subjects: 14
Study 23598900 — intervention group
Group type: COMPARATOR
Intervention: Treadmill gait training
Number of subjects: 14
Study 21527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ inserted in the abdomen
Number of subjects: 63
Study 21527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ inserted in the buttocks
Number of subjects: 63
Study 21527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ combined data from both sites
Number of subjects: 63
Study 21527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ at abdomen site
Number of subjects: 63
Study 21527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ at buttocks site
Number of subjects: 63
Study 21527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™
Number of subjects: 63
Study 19444280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ARB monotherapy (olmesartan medoxomil at 40 mg day(-1))
Number of subjects: 1200
Study 19444280 — intervention group
Group type: COMPARATOR
Intervention: ARB plus CCB combination therapy (20 mg day(-1) olmesartan with amlodipine or azelnidipine)
Number of subjects: 1200
Study 16762125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawthorn extract (1200 mg daily)
Number of subjects: 79
Study 16762125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 15628632 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy (high-frequency transcutaneous and intranasal electric stimulation of nasal muscles for 15 minutes, 3 times a week for 10 weeks)
Number of subjects: 40
Study 15628632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11688933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein formula enriched with arginine, fiber, and antioxidants
Number of subjects: 220
Study 11688933 — intervention group
Group type: COMPARATOR
Intervention: Standard high-protein formula
Number of subjects: 220
Study 11688933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein formula enriched with arginine, fiber, and antioxidants (for >2 days)
Number of subjects: 220
Study 11688933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein formula enriched with arginine, fiber, and antioxidants (for medical patients)
Number of subjects: 220
Study 11688933 — intervention group
Group type: COMPARATOR
Intervention: Standard high-protein formula (for medical patients)
Number of subjects: 220
Study 9457607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (5 mg/kg, twice daily, 1 h infusions)
Number of subjects: 72
Study 9457607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 7898905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrigid internal fixation and 6 weeks of maxillomandibular fixation (Group 1)
Number of subjects: 33
Study 7898905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid internal fixation and immediate postoperative function (Group 2)
Number of subjects: 33
Study 7898905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid internal fixation with maxillomandibular fixation for a mean of 14 days (Group 3)
Number of subjects: 33
Study 3074614 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg before sleeping)
Number of subjects: 117
Study 3074614 — intervention group
Group type: COMPARATOR
Intervention: Betahistine dichlorhydrate (8 mg 3 times daily)
Number of subjects: 117
Study 30561638 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0
Study 28019091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (0.3-10.0 mg/kg)
Number of subjects: 1895
Study 28019091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1895
Study 25852210 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of acute-phase reactants (fibrinogen, C-reactive protein)
Number of subjects: 886
Study 25852210 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of thrombolytic factors (fibrinogen, active and total plasminogen activator inhibitor [PAI]-1)
Number of subjects: 886
Study 25852210 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of cytokines/adipokines (tumor necrosis factor receptor-1 and -2, active and total PAI-1, IL-6)
Number of subjects: 886
Study 25852210 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction score
Number of subjects: 886
Study 23984885 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity setting of the Actiwatch
Number of subjects: 10
Study 23984885 — intervention group
Group type: COMPARATOR
Intervention: Low sensitivity setting of the Actiwatch
Number of subjects: 10
Study 20660503 — intervention group
Group type: EXPERIMENTAL
Intervention: LLHA made of 0.9 mm SS wire
Number of subjects: 44